NASDAQ : DCTH

Delcath Systems, Inc. — Company profile

Healthcare · Medical Devices · United States

Last price 14.64 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 507.99M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.

Details

NameDelcath Systems, Inc.
SectorHealthcare
IndustryMedical Devices
Employees156
Founded1988
CeoGerard Michel
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS24661P8077
Cusip24661P807
Cik0000872912
Sic3841
Stock TypeCommon Stock

Key executives

NameTitle
Gerard J. Michel MBA, MSChief Executive Officer and Director
Dr. Martha S. Rook Ph.D.Chief Operating Officer
Dr. Vojislav Vukovic M.D., M.Sc., Ph.D.Chief Medical Officer
Sandra Pennell CPAChief Financial Officer
David Hoffman J.D.General Counsel, Corporate Secretary and Chief Compliance Officer
Kevin MuirChief Commercial Officer
Dr. Michael Brunner M.D.Senior Vice President of Interventional Oncology

Contact

Address566 Queensbury Avenue, Queensbury, New York 12804, United States
Phone212 489 2100
Websitehttps://www.delcath.com